TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $128,441 | -41.5% | 14,367 | +0.5% | 0.00% | -100.0% |
| Q2 2023 | $219,664 | -16.7% | 14,301 | +21.9% | 0.00% | 0.0% |
| Q1 2023 | $263,830 | -5.1% | 11,731 | -11.3% | 0.00% | 0.0% |
| Q4 2022 | $278,143 | -6.7% | 13,226 | +9.4% | 0.00% | 0.0% |
| Q3 2022 | $298,000 | +4.6% | 12,094 | +2.6% | 0.00% | 0.0% |
| Q2 2022 | $285,000 | -37.2% | 11,788 | -33.1% | 0.00% | 0.0% |
| Q1 2022 | $454,000 | -32.1% | 17,632 | -18.1% | 0.00% | 0.0% |
| Q4 2021 | $669,000 | +34.9% | 21,523 | +5.3% | 0.00% | 0.0% |
| Q3 2021 | $496,000 | +30.9% | 20,438 | -21.4% | 0.00% | 0.0% |
| Q2 2021 | $379,000 | -33.3% | 25,987 | +14.2% | 0.00% | -50.0% |
| Q1 2021 | $568,000 | +11.4% | 22,756 | +21.6% | 0.00% | 0.0% |
| Q4 2020 | $510,000 | – | 18,718 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |